European Union · Record · QUESTION_WRITTEN_PRIORITY
P-9-2021-002543
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
Introduced
12 May 2021
Last action
—
Status
QUESTION_WRITTEN_PRIORITY
Sponsors
—
Subjects
Discovery layer
Source updated
12 May 2021
Official titles
Authentic titles published by the source. The stored canonical title is not replaced.
1 official language
English
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
Records
Official record P-9-2021-002543 from European Union at European Parliament. Dated 12 May 2021. Status: QUESTION_WRITTEN_PRIORITY.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
7 official files
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
QUESTION_WRITTEN_PRIORITY · EN · 18 May 2021
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
QUESTION_WRITTEN_PRIORITY · EN · 18 May 2021
Supply of surplus Pfizer/BioNTech vaccine at cost price to developing countries
QUESTION_WRITTEN_PRIORITY · EN · 18 May 2021
Answer
QUESTION_WRITTEN_ANSWER
Levering van overschot Pfizer/BioNTech-vaccin tegen kostprijs aan landen in ontwikkeling
QUESTION_WRITTEN_PRIORITY · NL · 18 May 2021
Levering van overschot Pfizer/BioNTech-vaccin tegen kostprijs aan landen in ontwikkeling
QUESTION_WRITTEN_PRIORITY · NL · 18 May 2021
Levering van overschot Pfizer/BioNTech-vaccin tegen kostprijs aan landen in ontwikkeling
QUESTION_WRITTEN_PRIORITY · NL · 18 May 2021
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.